Skip to main content
Fig. 4 | BMC Cardiovascular Disorders

Fig. 4

From: HiPSC-derived cardiomyocyte to model Brugada syndrome: both asymptomatic and symptomatic mutation carriers reveal increased arrhythmogenicity

Fig. 4

Action potential (AP) characteristics of ventricular-like CMs. Representative action AP traces from (A) WT, (B) asymptomatic and (C) symptomatic CMs respectively. Arrows indicate the arrhythmias in asymptomatic and symptomatic CMs. (D) Percentage of arrhythmia occurrences in WT (3.4%, n = 1/29), asymptomatic (n = 11/41) and symptomatic (n = 6/36) CMs. Averaged values and comparison of (E) beat per minute (BPM), (F) upstroke velocity (Vmax), (G) AP duration at 50% (APD50) and 90% (APD90) repolarization, and (H) AP amplitude (APA) and maximum diastolic potential (MDP). (I) Representative AP with prominent spike and dome morphology. Inset: enlarged version of AP. Numbers in parenthesis represent the number of cells used. * or # P < 0.05 * WT vs. asympt, # WT vs. sympt. Data are presented as mean ± S.E.M.

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us